TRVITrevi Therapeutics, Inc.
$13.20+62% 1Y
$13.20
$8.3852 weeks$19.08
TRVI as reported
- Net income
- −$51M
Net income · +8.1% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$53M
Free cash flow · trailing twelve months to Q2 2026
- EPS
- −$0.34
EPS · −19% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$51M | +8.1% | Q2 2026 |
| EPS | −$0.34 | −19% | Q2 2026 |
| ROE | −22% | n/a | Q2 2026 |
| ROA | −21% | n/a | Q2 2026 |
| Free cash flow | −$53M | n/a | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Trevi Therapeutics, Inc. (TRVI) · Net incomeNet incomeTrevi Therapeutics, Inc. (TRVI)